

We are a publishing house dedicated to providing high quality course materials including textbooks, readers, and casebooks.

We also publish books of general interest to the wider reading public.

We offer a range of innovative solutions for your publishing needs. Get the benefit of Linus' unique production line all the way from pre press designing to custom marketing.

Our versatility enables last minute changes that will allow you to control the project in all its stages. Our personalized service to customers will take you to the "next level" of publishing industry.

Linus Publications, Inc
65-12, Brook Avenue,
Deer Park, NY 11729
Tel: 631 274 5700, 866 493 4456
Fax: 631 242 0369
E-mail: info@linusbooks.com
Web: www.linusbooks.com

Online ordering www.linusbooks.com

Myasthenia Gravis

Disease Mechanisms and Immune Intervention

This book will present the current concept of autoimmune myasthenia gravis (MG) pathogenesis and strategy for specific therapy or cure for MG. MG is a classical autoimmune disease of the nervous system for which the target antigen, nicotinic acetylcholine receptor, has been cloned, sequenced and biochemically characterized. Antibodies to acetylcholine receptors and complement destroy acetylcholine receptor at the neuromuscular junction, thus leading to defective neuromuscular transmission, muscle fatigue and weakness. Target antigens have been characterized for only a very few other autoimmune diseases. Therefore, MG serves as a prototype for other autoimmune diseases, especially antibody-and/or complement-mediated autoimmune diseases (e.g., Graves disease, SLE, hemolytic anemia, pemphigus, etc.)

In the last few years, rapid advances have been made in unraveling the cellular and molecular mechanisms involved in the pathogenesis of MG, both in the animal model of experimental autoimmune MG (EAMG), and in human MG. Significant advances are being made in characterizing the cells and molecules involved in the autoimmune response to the acetylcholine receptor (AChR) and the MUSK protein. Preclinical and clinical trials have been performed utilizing the information gained in basic research. These advances are leading to the development of specific methods of immune intervention for MG.

Since there are rapid advances and numerous publications on MG and EAMG, it is important to compile the literature on MG research containing a timely review of specific topics. Thus, this book focuses on recent published data and how it is integrated into the present knowledge of MG. The chapters in this book have been contributed by world-renowned authors in US, Europe and China working in the area of MG.

Part I of the book chapters focuses on the clinical features, diagnosis, lab investigation, immunopathogenesis and current treatment of all forms of MG. Included in Part I are chapters on the genetics of MG and the role of thymus and BAFF in MG pathogenesis. Lambert Eaton syndrome and congenital MG are discussed in Parts II and III, respectively. Part IV deals with the role of T cells, B cells, complement, cytokines and chemokines in the experimental autoimmune MG. Further the immunopathogenesis of the new mouse model of MUSK-induced EAMG is discussed. The pre-clinical trial section is Part V. Here the role of regulatory cells, dendritic cells, IV Ig and Pixantrone in immune modulation is reviewed. Other avenues of treatment of MG by blocking classical complement pathway and IL-6 and antigen specific apheresis are also discussed. Also there is a chapter on antisense cholinesterase inhibitor. The book concludes with a clinical trial section in Part VI. Clinical trials on etanercept and retuximab are presented.


The target audience consists of basic scientists and clinical scientists in the university, as well as clinicians, industry researchers, graduate students, medical students and postdoctoral fellows interested in autoimmune disease or neuroimmunology research. The purpose is to educate the physician on the newest clinical trials and to educate the scientists on the complexity of the immune system in antibody-and complement-mediated diseases. Medical students and clinicians will learn the current diagnosis and treatment of MG. Graduate students will not only be interested in reading the latest in EAMG/MG research, but also will find information to help them develop a future strategy to unravel the precise mechanism of disease and development specific therapy. Further, the book will be an ideal tool to apply basic and clinical knowledge gained in MG research to other autoimmune disease research.

Premkumar Christadoss, M.B.B.S.

Myasthenia Gravis

Disease Mechanisms and Immune Intervention

Second Edition



Edited by

Premkumar Christadoss

Table of Contents

I. MYASTHENIA GRAVIS

Chapter 01

Myasthenia Gravis Clinical Features, Diagnosis and Lab Investigations.

Chapter 02

Pathogenic Mechanisms in Myasthenia Gravis

Chapter 03

Ocular Myasthenia: Diagnosis, Treatment and Pathogenesis

Chapter 04

Myasthenia Gravis Therapy and Thymectomy

Chapter 05

Plasma exchange and immunoadsorption for myasthenia gravis

Chapter 06

Evidence-based Efficacy of Intravenous Immunoglobulin Therapy in Human Myasthenia Gravis and Mechanisms of Action

Chapter 07

Genetics of human autoimmune myasthenia gravis

Chapter 08

Thymoma Pathology and Thymoma-associated Myasthenia gravis

Chapter 09

Dysregulation of the immune system in human Myasthenia Gravis: Possible role in pathogenesis

Chapter 10

The Role of BAFF in Autoimmunity and Myasthenia Gravis

II. LAMBERT-EATON MYASTHENIC SYNDROME

Chapter 11

Lambert-Eaton Myasthenic Syndrome

III. CONGENITAL MYASTHENIC SYNDROME

Chapter 12

Congenital Myasthenic Syndromes

IV. EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS

Chapter 13

Mechanisms of Tolerance in Experimental Models of Myasthenia Gravis

Chapter 14

Effector Functions of IgG Isotypes in Myasthenia Gravis

Chapter 15

Myasthenia Gravis: The Influence of Complement and its Regulatory Proteins

Chapter 16

Chemokines and Chemokine receptors in Myasthenia Gravis and Experimental Autoimmune Myasthenia Gravis

Chapter 17

The Immunopathogenesis of Experimental Autoimmune Myasthenia Gravis Induced by Autoantibodies against Muscle-specific kinase

V. PRECLINICAL TRIALS IN MYASTHENIA GRAVIS

Chapter 18

Targeting Classical Complement Pathway and IL-6 in Experimental autoimmune Myasthenia Gravis

Chapter 19

CD4+CD25+ Regulatory T cells in Myasthenia Gravis

Chapter 20

Generation of Regulatory Immune Cells Utilizing Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Experimental Myasthenia Gravis

Chapter 21

Dendritic cells for the antigen specific therapy of Experimental Autoimmune Myasthenia Gravis

Chapter 22

Pixantrone: Preclinical Studies in EAMG

Chapter 23

Antigen-specific apheresis of autoantibodies as a treatment strategy for myasthenia gravis

Chapter 24

IVIg in Experimental Autoimmune Myasthenia Gravis: Mechanisms of Immunosuppression

Chapter 25

Treatment with Anti-sense Targeted to Acetylcholinesterase in Myasthenia gravis and Experimental Autoimmune Myasthenia gravis

VI. CLINICAL TRIALS IN MYASTHENIA GRAVIS

Chapter 26

The Rationale for Tumor Necrosis Factor Antagonism (Etanercept) in the Treatment of Autoimmune Myasthenia Gravis

Chapter 27

Myasthenia Gravis and Rituximab



Review Copy Request Form

Name: _____

University: _____

Department: _____

Enrollment: _____

Street: _____

Zip Code: _____

Telephone: _____

E-mail: _____

65-12, Brook Avenue
Deer Park, NY 11729
Tel: 866 493 4456
Fax: 631 242 0369
info@linusbooks.com
www.linusbooks.com



Online ordering www.linusbooks.com

